2022
International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis
Bewersdorf J, Grimshaw A, Platzbecker U, Fenaux P, Sekeres M, Zeidan A, Stahl M. International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis. Blood 2022, 140: 9811-9812. DOI: 10.1182/blood-2022-158622.Peer-Reviewed Original Research
2020
Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis
Bewersdorf J, Tallman M, Cho C, Zeidan A, Stahl M. Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis. Blood 2020, 136: 34-35. DOI: 10.1182/blood-2020-136671.Peer-Reviewed Original ResearchAcute myeloid leukemiaRelapse-free survivalAllogeneic hematopoietic cell transplantHematopoietic cell transplantFLT3 inhibitorsMyelodysplastic syndromeAllo-HCTOverall survivalRFS ratesChronic GVHDMaintenance therapyCell transplantPatient selectionClinical trialsMyeloid leukemiaADC therapeuticsSystematic reviewMinimal residual disease testingAdvisory CommitteeDaiichi SankyoHigh-risk geneticsRate of GVHDPre-emptive treatmentCareful patient selectionPrognosis of patients
2018
Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Annals Of Hematology 2018, 98: 339-350. PMID: 30413901, DOI: 10.1007/s00277-018-3539-7.Peer-Reviewed Original ResearchConceptsIntermediate-risk myelodysplastic syndromesIron chelation therapyAcute myeloid leukemiaOverall survivalMyelodysplastic syndromeIron overloadSystematic reviewChelation therapyWorld Health Organization Clinical Trials RegistryInternational Prognostic Scoring System lowLower-risk myelodysplastic syndromesClinical Trials RegistryRisk of progressionRisk of mortalityOverall low riskHazard ratio estimatesRandom-effects modelNonrandomized trialsTrials RegistryCochrane DatabaseDisease progressionBias riskMyeloid leukemiaObservational studyLower riskThe effect of iron chelation therapy on overall survival in sickle cell disease and β‐thalassemia: A systematic review
Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and β‐thalassemia: A systematic review. American Journal Of Hematology 2018, 93: 943-952. PMID: 29635754, DOI: 10.1002/ajh.25103.Peer-Reviewed Original ResearchConceptsIron chelation therapySickle cell diseaseEvent-free survivalChelation therapyOverall survivalCell diseaseΒ-thalassemiaSystematic reviewRed blood cell transfusionBlood cell transfusionBetter overall survivalSerum ferritin levelsLife-threatening anemiaTransfusion-dependent patientsStandard of careIron chelation agentsLiver iron contentNew oral drugsCell transfusionFrequent transfusionsOral agentsDiabetes mellitusHeart failureLiver cirrhosisFerritin levelsMore is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
Shallis RM, Zeidan AM. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 2018, 18: 4. PMID: 29435332, PMCID: PMC5796398, DOI: 10.1186/s12878-018-0095-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHigh-risk myelodysplastic syndromeMyelodysplastic syndromeAcute myeloid leukemiaAdministration scheduleOverall survivalLower-risk myelodysplastic syndromesAlternative administration schedulesOutcomes of patientsAlternative dosing schedulesRisk of progressionMeaningful clinical responsesAgent azacitidineAZA-001Clinical responseConventional careDosing schedulesPeripheral cytopeniasProspective studyClinical trialsHematologic disordersMyeloid leukemiaMost trialsResponse ratePatientsSystematic review